Biotech
Monday, June 24th, 2024 2:54 pm EDT
Key Points
- Ventripoint Diagnostics Ltd. will present its AI-enhanced cardiac ultrasound technology at The Data Effect conference in Vancouver, showcasing MRI-quality cardiac measurements generated quickly and cost-effectively.
- CEO Hugh MacNaught will participate in a panel discussing the impact of AI and digital health in Canadian healthcare, joined by other notable leaders in the field.
- Ventripoint’s VMS+ technology, which converts 2D ultrasound scans into 3D images of the heart, has received regulatory clearance in multiple regions and is used in leading hospitals globally.
Toronto, Ontario – TheNewswire – June 24, 2024 –Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”), (TSXV:VPT); (OTC:VPTDF) has been selected to present its AI-enhanced cardiac ultrasound technology, which generates MRI-quality cardiac measurements in minutes, to health-care leaders at The Data Effect on June 25th in Vancouver.
CEO Hugh MacNaught will be on the panel Accelerating AI Startups in Canadian Health Care, which explores applications of AI and digital health with global impact.
He is being joined on this panel at The Data Effect by other health care leaders, including: Maryam Sadeghi PhD, CEO & Co-Founder of MetaOptima; Lloyd Jura, a Professor specializing in AI and cybersecurity at New York Institute of Technology; Tiffany Chiu, AbCellera’s Vice-President of Communications; and the Vancouver-based innovator Dr. Alexandra T Greenhill, CEO of CareTeam Technologies.
“This is an important forum to meet the innovators as well as the health care and hospital thought leaders who are at the lead of bringing new approaches to data and AI to provincial health care systems,” said MacNaught. “We are delighted to have been invited to The Data Effect, as we introduce Ventripoint innovations to hospitals around Canada and the world.”
Ventripoint’s VMS+ easily interfaces with all major brands of echocardiography machines and transforms 2D ultrasound scans into 3D images of all four chambers of the heart more rapidly and at less expense than cardiac MRI. VMS+ has received clearance by FDA, and is licensed for sale by Health Canada and regulators in the UK and EU. It is now being used in leading hospitals in Canada, the US, Germany and the UK.
The Data Effect has been gathering Canada’s health care leaders together for more than a decade, to highlight technologies and ideas to improve health care for caregivers and patients. The Vancouver Data Effect, part of an ongoing series looking at AI and data in health care and other sectors, is being attended by more than 125 health care leaders.
The focus of the Vancouver conference is on how Canadian technologies, data and AI can advance health care solutions and patient care. It is part of The Data Effect ‘s stated mission to bring together leaders and technologies to “explore how new approaches in health data stewardship and AI – in combination with innovations in health campus design and life science research – can drive better health services in Canada and build our global profile.“
For further information, please contact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.
Copyright (c) 2024 TheNewswire – All rights reserved.
